Leerink Partners analyst David Risinger has maintained their neutral stance on VRTX stock, giving a Hold rating on July 7.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Hold rating due to a combination of factors impacting Vertex Pharmaceuticals. One significant aspect is the recent price increase of Trikafta, which matches the launch price of the new once-daily Alyftrek. This pricing strategy may have led to increased inventory purchases at the end of the second quarter, potentially benefiting future financial results. However, the analyst has not yet received direct commentary from the company’s management, and further insights are anticipated with the upcoming quarterly results.
Additionally, the transition from Trikafta to Alyftrek involves considerations that may slow down patient switching. Patients moving to Alyftrek are required to undergo monthly liver monitoring for six months, which could affect the rate at which they transition. These factors, along with the current market dynamics and patient preferences, contribute to the decision to maintain a Hold rating on VRTX shares.
According to TipRanks, Risinger is a 5-star analyst with an average return of 9.1% and a 54.27% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and AbbVie.
In another report released on July 7, RBC Capital also maintained a Hold rating on the stock with a $430.00 price target.